Ilixadencel, an allogeneic cell therapy developed by Immunicum AB of Sweden, has achieved complete tumour responses in five out of 45 evaluable patients with metastatic kidney cancer in a Phase 2 trial, compared with just one out of 25 patients receiving standard-of care sunitinib. Announcing the results on 29 August, the company said the data support its vision of positioning ilixadencel as a “backbone therapy” for modern cancer treatment regimens.
